Zhuhai Rundu Pharmaceutical Co., Ltd. (SHE:002923)
China · Delayed Price · Currency is CNY 10.17
-0.30 (-2.87%)
Jul 30, 2026, 3:04 PM CST
SHE:002923 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,252 | 1,158 | 1,177 | 1,282 | 1,363 | 1,188 |
Other Revenue | 18.08 | 18.08 | 5.53 | 10.06 | 9.01 | 1.98 |
| 1,270 | 1,176 | 1,182 | 1,292 | 1,372 | 1,190 | |
Revenue Growth | 12.32% | -0.51% | -8.48% | -5.85% | 15.32% | -5.01% |
Cost of Revenue | 803.49 | 764.61 | 691.9 | 685.03 | 636.32 | 478.84 |
Gross Profit | 466.88 | 411.75 | 490.47 | 606.86 | 735.92 | 711.09 |
Selling, General & Admin | 381.55 | 332.14 | 310.35 | 392.51 | 459.74 | 475.85 |
Research & Development | 81.05 | 92.38 | 129.2 | 127.3 | 92.34 | 84.27 |
Other Operating Expenses | 13.67 | 12.62 | 11.78 | 15.46 | 15.25 | 12 |
Operating Expenses | 478.78 | 438.31 | 451.46 | 535.43 | 569.89 | 572.6 |
Operating Income | -11.9 | -26.57 | 39.01 | 71.43 | 166.02 | 138.49 |
Interest Expense | -12.89 | -13.11 | -15.78 | -16.12 | -6.97 | -1.77 |
Interest & Investment Income | 1.63 | 1.67 | 1.33 | 2.25 | 1.48 | 2.33 |
Currency Exchange Gain (Loss) | -0.38 | -0.38 | 2.85 | 1.76 | 1.3 | -1.34 |
Other Non Operating Income (Expenses) | -6.82 | -5.08 | -1.94 | -0.4 | -0.45 | -0.86 |
EBT Excluding Unusual Items | -30.36 | -43.46 | 25.47 | 58.92 | 161.38 | 136.84 |
Merger & Restructuring Charges | -13.32 | -13.32 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.01 | -0.01 | 0.01 | -0.36 | -0.02 | -0.02 |
Gain (Loss) on Sale of Assets | 1.07 | 0.63 | - | 27.58 | 0.05 | - |
Asset Writedown | -16.38 | -16.78 | -0.43 | -0.18 | -0.33 | -0.23 |
Other Unusual Items | 13.45 | 13.36 | 17.58 | 0.09 | 19.86 | 15.14 |
Pretax Income | -45.55 | -59.59 | 42.63 | 86.04 | 180.94 | 151.74 |
Income Tax Expense | 4.19 | 3.88 | 2.74 | 19.14 | 25.46 | 11.97 |
Net Income | -49.74 | -63.47 | 39.88 | 66.9 | 155.48 | 139.77 |
Net Income to Common | -49.74 | -63.47 | 39.88 | 66.9 | 155.48 | 139.77 |
Net Income Growth | - | - | -40.38% | -56.97% | 11.24% | 2.87% |
Shares Outstanding (Basic) | 365 | 334 | 332 | 334 | 338 | 337 |
Shares Outstanding (Diluted) | 365 | 334 | 332 | 334 | 338 | 337 |
Shares Change | 22.46% | 0.51% | -0.64% | -1.04% | 0.19% | 0.96% |
EPS (Basic) | -0.14 | -0.19 | 0.12 | 0.20 | 0.46 | 0.41 |
EPS (Diluted) | -0.14 | -0.19 | 0.12 | 0.20 | 0.46 | 0.41 |
EPS Growth | - | - | -40.00% | -56.52% | 11.03% | 1.89% |
Free Cash Flow | 126.02 | 86.44 | 129.94 | -1.85 | -116.75 | -170.58 |
Free Cash Flow Per Share | 0.34 | 0.26 | 0.39 | -0.01 | -0.34 | -0.51 |
Dividend Per Share | - | - | 0.150 | 0.200 | 0.250 | 0.220 |
Dividend Growth | - | - | -25.00% | -20.00% | 13.74% | 0% |
Gross Margin | 36.75% | 35.00% | 41.48% | 46.98% | 53.63% | 59.76% |
Operating Margin | -0.94% | -2.26% | 3.30% | 5.53% | 12.10% | 11.64% |
Profit Margin | -3.91% | -5.40% | 3.37% | 5.18% | 11.33% | 11.75% |
Free Cash Flow Margin | 9.92% | 7.35% | 10.99% | -0.14% | -8.51% | -14.34% |
EBITDA | 131.13 | 114.62 | 172.8 | 182.29 | 235.45 | 198.39 |
EBITDA Margin | 10.32% | 9.74% | 14.61% | 14.11% | 17.16% | 16.67% |
D&A For EBITDA | 143.04 | 141.19 | 133.79 | 110.86 | 69.43 | 59.91 |
EBIT | -11.9 | -26.57 | 39.01 | 71.43 | 166.02 | 138.49 |
EBIT Margin | -0.94% | -2.26% | 3.30% | 5.53% | 12.10% | 11.64% |
Effective Tax Rate | - | - | 6.44% | 22.25% | 14.07% | 7.89% |
Revenue as Reported | 1,270 | 1,176 | 1,182 | 1,292 | 1,372 | 1,190 |